Sex, n (%)
Female
Male
|
14 (25.9)
40 (74.1)
|
58 (50)
58 (50)
|
0.003
|
APACHE II (mean±SD) |
20.9±7.6 |
25.74±6.6 |
<
0.001 |
Underlying diseases, n (%)
Chronic obstructive pulmonary disease
Diabetes mellitus
Cardiac failure
Coronary artery disease
Immunosuppression
Solid organ malignancy
|
17 (31.5)
12 (22.2)
3 (5.6)
5 (9.3)
8 (14.8)
1 (1.9)
|
69 (59.5)
32 (27.6)
30 (25.9)
35 (30.2)
6 (5.2)
3 (2.6)
|
0.001
0.457
0.002
0.003
0.067
1.0
|
Initial serum urea (mg/dL) median (min-max) |
39 (11-99) |
48 (9-125) |
0.041 |
Initial serum creatinine (mg/dL) median (min-max) |
0.65 (0.3-1.2) |
0.77 (0.3-1.2) |
0.018 |
COL nephrotoxicity, n (%) |
18 (33.3) |
88 (75.9) |
<
0.001 |
Concomitant nephrotoxic agent use, n (%) |
28 (50.3) |
83 (65.9) |
0.07 |
Vasopressor agent use, n (%) |
13 (24.1) |
73 (62.9) |
< 0.001 |
End-treatment serum urea (mg/dL) median (min-max) |
49 (8-266) |
93.5
(10-295) |
< 0.001 |
End-treatment serum creatinine (mg/dL) median (min-max) |
0.83
(0.21-5.68) |
1.96 (0.3-8) |
< 0.001 |
14-day mortality, n (%) |
12 (22.2) |
60 (51.7) |
<
0.001 |
28-day mortality, n (%) |
15 (34.9) |
40 (71.4) |
<
0.001 |
Overall mortality, n (%) |
35 (64.8) |
107 (92.2) |
<
0.001 |